Hypothesis

**Intermittent hypoxia preconditioning (IHP) of aged c‑Kit+ cardiac progenitor cells (CPCs) activates HIF‑2α, which drives mitophagy and suppresses the senescence‑associated secretory phenotype (SASP), thereby restoring proliferative and differentiation capacity without requiring senolytics.

Rationale

Aged CPCs show mitochondrial dysfunction, increased senescence‑associated β‑galactosidase activity (~60% vs ~35% in young) and elevated p16, leading to a SASP that propagates dysfunction {1,2}. This secretory milieu impairs proliferation and differentiation, limiting cardiac regeneration.

Mechanistic Insight

While HIF‑1α is often linked to hypoxia‑induced glycolysis, recent data indicate HIF‑2α preferentially regulates mitophagy genes BNIP3 and NIX, enhances lysosomal clearance of damaged mitochondria, and inhibits the NLRP3 inflammasome, thereby lowering IL‑6 and IL‑8 secretion. HIF‑2α also sustains LIN28 expression, preserving a stem‑like state and promoting a transient glycolytic shift that reduces ROS accumulation. Consequently, IHP‑induced HIF‑2α activation rejuvenates CPCs by clearing dysfunctional mitochondria and dampening SASP.

Testable Predictions

1. IHP will increase mitophagy flux in aged CPCs, measurable by rising LC3‑II/I ratio and mt‑Keima signal.
2. Genetic knock‑down of HIF‑2α will abolish the IHP‑induced improvements in mitophagy and SASP suppression.
3. SASP factors (IL‑6, IL‑8, MMP‑3) will decrease significantly after IHP.
4. Proliferation (Ki67+/EdU+) and cardiac differentiation (cTnT, αSMA) markers will rise in IHP‑treated CPCs.
5. In a murine myocardial infarction model, transplantation of IHP‑preconditioned aged CPCs will yield greater ejection fraction improvement compared with untreated or senolytic‑treated cells.

Experimental Approach

Isolate CPCs from 20‑month‑old mice. Expose cells to cyclic hypoxia: 5% O2 for 2 h followed by 22 % O2 for 2 h, repeated three times daily for 48 h. Assess HIF‑2α protein by Western blot, mitophagy via LC3‑II/I and mt‑Keima fluorescence, SASP cytokines by ELISA, and proliferation/differentiation by flow cytometry and immunostaining. Include HIF‑2α siRNA and dasatinib+quercetin controls. Validate findings in vivo by intramyocardial injection of treated CPCs post‑MI and monitor cardiac function by echocardiography over 4 weeks.